secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001628280-25-023808
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q1 revenue down 58% to $4.2M; net loss $45.6M; introduces ABCL635 for hot flashes
--------------------------------------------------------------------------------

- Total revenue $4.2M, down 58% from $10.0M in Q1 2024.
- Net loss $45.6M ($0.15/share) vs net loss $40.6M ($0.14) year ago.
- Announces ABCL635, a first-in-class NK3R antibody for vasomotor symptoms from menopause; Phase 1 expected H2 2025.
- Available liquidity ~$810M ($633M cash + $178M government funding).
- Cumulative partner program starts 97, clinic molecules 16; R&D spend up to $42.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000162828025023808/0001628280-25-023808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000162828025023808/abcl-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-023808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer